1. We've addressed a number of the issues raised in the previous survey. Please help us make sure we're aware of all issues by completing this new, short, confidential survey. Thank you!
  2. Need help finding a board? Read this post for help

Can't stop the bleeding

Discussion in 'Actelion' started by Anonymous, Nov 8, 2011 at 9:17 PM.

  1. Anonymous

    Anonymous Guest

    Be afraid very afraid!!!!!!!!!!! It's comin after the ra ra session. Get out if you can, the west is crumbling....
     
  2. Anonymous

    Anonymous Guest

    Deedee got rid of her third rep within a year..... Why does the upper mgnt not see it's Deedee!!!
     
  3. Anonymous

    Anonymous Guest

    Who departed?
     
  4. Anonymous

    Anonymous Guest

    Don't know who is gone, but the awards night was a complete snoozer. Would have rather gone out and had a nice meal and relaxed versus putting on my forced smile.
     
  5. Anonymous

    Anonymous Guest

    Looser!
     
  6. Anonymous

    Anonymous Guest

    Learn to spell, loser.
     
  7. Anonymous

    Anonymous Guest

    As our clueless managers keep firing reps (in order to cover up for their own ineptness), have you noticed the lower caliber of replacement hires? They're mostly young pups straight out of big pharma or with absolutely no pharma experience at all. Only clueless unskilled biotech labor are willing to take a chance on this dying company.
     
  8. Anonymous

    Anonymous Guest

    "Sales in the 12-month period fell 7 percent to 1.8 billion francs ($2 billion), as revenue from Tracleer declined by the same amount to 1.5 billion francs ($1.6 billion)."

    "CFO Andrew Oakley noted that the pricing environment will be "a little bit worse" in 2012. He added that Tracleer will also continue to lose ground to Gilead’s Letairis. "It’s not falling off a cliff, but it’s just slowly declining."

    http://www.firstwordpharma.com/node/952227
     
  9. Anonymous

    Anonymous Guest

    What is even worse is that listening to our earnings call, one of the questions was specifically about US sales force turnover. They said there has been no increase in turnover. A lie. There has been increased turnover, and there also have been vacant territories that were not back filled. The spin continues.
     
  10. Anonymous

    Anonymous Guest

    OOPS! "investors appeared to take notice when it was reported that 120 patients in a late-stage trial for the key drug (macitentan) had died, and the company's uncertain about what causes the deaths."

    ABANDON SHIP! "Clozel's comment quoted in Bloomberg that he thinks it's unlikely the trial for macitentan--which the company is hoping will replace revenue from its PAH drug Tracleer--will show a survival benefit."

    http://www.fiercebiotech.com/story/.../2012-02-14?utm_medium=nl&utm_source=internal
     
  11. Anonymous

    Anonymous Guest

    Not good. If macitentan does not show a survival benefit, it may be marginally better than Tracleer (lack of LFT's issues), then what do you have...Letairis. I hope not.
     
  12. Anonymous

    Anonymous Guest

    Everything the Clozels have touched after Tracleer has been a bust. They can't complete a clinical trial to save their souls, and we keep having to listen to how much smarter the Swiss are in science than we poor Americans. They're so smart apparently they don't know how dumb they come off to the investors.

    I give this place three months if the mac trials don't work out. Nobody will stand behind the Clozels and the investors will finally force them to sell.
     
  13. Anonymous

    Anonymous Guest

    The perfection of failure continues...

    April 2, 2012, 7:46 a.m. ET
    ZURICH (Dow Jones)--Actelion Holding AG (ATLN.VX) is terminating development of an experimental asthma and allergy medicine after it failed in two recent late stage studies, giving the company's allergy drug program a major setback. -- Makes looming macitentan trials even more vital for company's prospects.
     
  14. Anonymous

    Anonymous Guest


    Nah, were just setting everyone up for the great trial result for macitentan. Or at least we all hope so!
     
  15. Anonymous

    Anonymous Guest

    Damn....you must have a double dose of that Kool Aid...or you're inhaling some Ventavis. We WISH we were the market leader. Our competitors are killing us because our business is tanking. Oh, but wait....we're just not working hard enough! What the heck do you think is going to hit from our pipeline?? If it looked so good, why is no one saving our sinking ship? Let's deal with reality.
     
  16. Anonymous

    Anonymous Guest

    Wait!!!!!! Dick straightener will save us!
     
  17. Anonymous

    Anonymous Guest

    Maci hit endpoint! Bleeding stop! We may have a future!
     
  18. Anonymous

    Anonymous Guest

    Awesome news for anyone at Actelion today. Any current employee that is not thrilled about their future or the companies future, should just leave. And for the former employees that post posing as current colleagues......thanks for coming and drive home safely! Cause you are DONE!
     
  19. Anonymous

    Anonymous Guest

    How long until approval? Do you think it will be fast tracked even though there are two other ERAs? If not we have about 2 years until approval. Have we sent for approval yet? Can we hang on long enough? How long will there be a bb? A year or two? Letaris is killing me. One Tracleer a month is about the average in our district.
     

Share This Page